A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
- DOI
- 10.1002/cam4.6776
- Published
- 2024 Mar
- Container
- Cancer medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cam4.6776,
title = {A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.},
author = {Juric D and Barve M and Vaishampayan U and Roda D and Calvo A and Jañez NM and Trigo J and Greystoke A and Harvey RD and Olszanski AJ and Opyrchal M and Spira A and Thistlethwaite F and Jiménez B and Sappal JH and Kannan K and Riley J and Li C and Li C and Gregory RC and Miao H and Wang S},
year = {2024},
journal = {Cancer medicine},
doi = {10.1002/cam4.6776},
url = {https://doi.org/10.1002/cam4.6776}
}RIS
TY - JOUR TI - A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. AU - Juric D AU - Barve M AU - Vaishampayan U AU - Roda D AU - Calvo A AU - Jañez NM AU - Trigo J AU - Greystoke A AU - Harvey RD AU - Olszanski AJ AU - Opyrchal M AU - Spira A AU - Thistlethwaite F AU - Jiménez B AU - Sappal JH AU - Kannan K AU - Riley J AU - Li C AU - Li C AU - Gregory RC AU - Miao H AU - Wang S PY - 2024 JO - Cancer medicine DO - 10.1002/cam4.6776 UR - https://doi.org/10.1002/cam4.6776 ER -
APA
D, J., M, B., U, V., D, R., A, C., NM, J., J, T., A, G., RD, H., AJ, O., M, O., A, S., F, T., B, J., JH, S., K, K., J, R., C, L., C, L., RC, G., H, M., & S, W. (2024). A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.. Cancer medicine. https://doi.org/10.1002/cam4.6776
Source records
- pubmed · retrieved 2026-09-26T00:24:15.716Z